Harvard Bioscience (NASDAQ:HBIO) Stock Dropped to “Hold” by Stonex Financial

Harvard Bioscience (NASDAQ:HBIO – Get Free Report) was downgraded by analysts at Stonex Financial from a “moderate buy” rating to a “hold” rating in a research report issued on Wednesday, Zacks reports.

Other equities research analysts have also recently issued reports about the company. StoneX cut Harvard Bioscience from a “speculative buy” rating to a “hold” rating in a research report on Wednesday. Weiss Ratings upgraded Harvard Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Zacks Research initiated coverage on Harvard Bioscience in a report on Tuesday, November 3rd. They issued a “hold” rating for the company. Finally, Benchmark increased their price target on Harvard Bioscience from $6.00 to $7.50 and gave the stock a “speculative buy” rating in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Harvard Bioscience has an average rating of “Hold” and an average price target of $6.75.

View Our Latest Stock Analysis on HBIO

Harvard Bioscience Trading Down 4.8%

Shares of HBIO stock opened at $9.22 on Wednesday. Harvard Bioscience has a 52-week low of $4.00 and a 52-week high of $10.20. The business has a 50-day simple moving average of $8.31 and a 200-day simple moving average of $6.57. The company has a debt-to-equity ratio of 7.28, a current ratio of 1.76 and a quick ratio of 0.98.

Harvard Bioscience (NASDAQ:HBIO – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The medical instruments supplier reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.27. Harvard Bioscience had a negative return on equity of 43.94% and a negative net margin of 13.20%. The business had revenue of $22.20 million for the quarter, compared to analyst estimates of $21.80 million. Research analysts predict that Harvard Bioscience will post -2.44 earnings per share for the current year.

Hedge Funds Weigh In On Harvard Bioscience

An institutional investor recently bought a new stake in Harvard Bioscience stock. Meros Investment Management LP acquired a new stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 182,992 shares of the medical instruments supplier’s stock, valued at approximately $1,125,401. Meros Investment Management LP owned approximately 4.02% of Harvard Bioscience at the end of the most recent quarter. 80.87% of the stock is owned by hedge funds and other institutional investors.

About Harvard Bioscience

(Get Free Report)

Harvard Bioscience, Inc. (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies. The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.

Recommended Stories

Analyst Recommendations for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.